Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™. Issue 9 (1st September 2016)
- Record Type:
- Journal Article
- Title:
- Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™. Issue 9 (1st September 2016)
- Main Title:
- Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™
- Authors:
- Canelle, Quentin
Dewé, Walthère
Innis, Bruce L.
van der Most, Robbert - Abstract:
- ABSTRACT: In retrospective observational studies, an increased relative risk of incident narcolepsy was observed in some European countries among recipients of the AS03-adjuvanted, A(H1N1)pdm09, inactivated, detergent-split virion vaccine Pandemrix ™ manufactured in Dresden, Germany (D-Pan H1N1). A similar increased risk was not observed in a retrospective population-based study in individuals in Quebec province, Canada, who received Aprepanrix ™, a Quebec-manufactured AS03-adjuvanted A(H1N1)pdm09 inactivated, detergent-split virion vaccine (Q-Pan H1N1). Antibody responses in D-Pan versus Q-Pan vaccinees (adults/children) measured as hemagglutination inhibition (HI) titers 21 d post-vaccination were found to be equivalent (NCT01161160). The current post-hoc analysis was conducted to determine whether antibody avidity differed following immunization with the 2 vaccines. Using surface plasmon resonance, we evaluated the capacity of serum specimens (drawn from the comparative immunogenicity trial) from a subset of subjects aged 3–9 y who received either D-Pan or Q-Pan (N = 28/group), to bind to recombinant A(H1N1)pdm09 hemagglutinin. IgG antibodies were purified from Day 21 sera. Binding was assessed by end association level; dissociation by retention of antigen-antibody complexes at the end of the dissociation phase, and kd . Inter-run variability for the control monoclonal antibody, association levels and dissociation levels was low (CVs 1.3%, 7.8% and 1.4%, respectively);ABSTRACT: In retrospective observational studies, an increased relative risk of incident narcolepsy was observed in some European countries among recipients of the AS03-adjuvanted, A(H1N1)pdm09, inactivated, detergent-split virion vaccine Pandemrix ™ manufactured in Dresden, Germany (D-Pan H1N1). A similar increased risk was not observed in a retrospective population-based study in individuals in Quebec province, Canada, who received Aprepanrix ™, a Quebec-manufactured AS03-adjuvanted A(H1N1)pdm09 inactivated, detergent-split virion vaccine (Q-Pan H1N1). Antibody responses in D-Pan versus Q-Pan vaccinees (adults/children) measured as hemagglutination inhibition (HI) titers 21 d post-vaccination were found to be equivalent (NCT01161160). The current post-hoc analysis was conducted to determine whether antibody avidity differed following immunization with the 2 vaccines. Using surface plasmon resonance, we evaluated the capacity of serum specimens (drawn from the comparative immunogenicity trial) from a subset of subjects aged 3–9 y who received either D-Pan or Q-Pan (N = 28/group), to bind to recombinant A(H1N1)pdm09 hemagglutinin. IgG antibodies were purified from Day 21 sera. Binding was assessed by end association level; dissociation by retention of antigen-antibody complexes at the end of the dissociation phase, and kd . Inter-run variability for the control monoclonal antibody, association levels and dissociation levels was low (CVs 1.3%, 7.8% and 1.4%, respectively); non-specific binding was negligible. High avidity and slow dissociation was observed for both groups (kd ≤ 10 −4 /s; geometric mean [IQR] association and dissociation levels for D-Pan/Q-Pan: 15.4 RU [13.4–17.7]/12.4 RU [10.8–14.3] and 94.5% [92.5–96.5]/95.5% [93.5–97.6], respectively). Association, but not dissociation levels correlated with HI titers. No significant differences in avidity parameters were observed between D-Pan and Q-Pan sera. … (more)
- Is Part Of:
- Human vaccines & immunotherapeutics. Volume 12:Issue 9(2016)
- Journal:
- Human vaccines & immunotherapeutics
- Issue:
- Volume 12:Issue 9(2016)
- Issue Display:
- Volume 12, Issue 9 (2016)
- Year:
- 2016
- Volume:
- 12
- Issue:
- 9
- Issue Sort Value:
- 2016-0012-0009-0000
- Page Start:
- 2289
- Page End:
- 2298
- Publication Date:
- 2016-09-01
- Subjects:
- antibody -- AS03 -- Arepanrix -- avidity -- H1N1 -- hemagglutinin -- immunogenicity -- narcolepsy -- Pandemrix -- vaccine
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.tandfonline.com/toc/khvi20/current ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/21645515.2016.1168954 ↗
- Languages:
- English
- ISSNs:
- 2164-5515
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4336.468655
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 2090.xml